# David Kuraguntla

> David Kuraguntla is the co-founder and CEO of Alio, a medical technology company that grew from an implantable sensor concept into an FDA-cleared, multi-metric remote monitoring platform. Trained in biochemistry, neuroscience research, and osteopathic medicine, he has spent more than a decade translating clinical observations into regulated hardware, software, partnerships, and a durable operating philosophy: identify the largest risk early, align the people around it, and be willing to change the product without changing the purpose.

- **Role:** Co-founder and CEO at Alio
- **Organizations:** Alio, National Institute on Drug Abuse, United States Air Force, Grove City College, West Virginia School of Osteopathic Medicine
- **Education:** B.S. in Biochemistry, Grove City College, Master's degree, Boston University School of Medicine, Doctor of Osteopathic Medicine, West Virginia School of Osteopathic Medicine
- **Known for:** Co-founded Alio in 2012 and led its evolution from an implantable sensor concept to an end-to-end wearable remote monitoring platform., Led Alio through multiple FDA 510(k) clearances, including K211365 and K223073., Led financing rounds including a $20 million Series B in 2021 and an $18 million initial Series C close in 2022.

## Career timeline

- **2003** — Completed a National Science Foundation research internship while studying biochemistry.
- **2004-2006** — Worked in research at the National Institute on Drug Abuse; contributed to neuroscience publications.
- **2007** — Co-authored research on dopamine transporter function published in the Journal of Biological Chemistry.
- **2008-2012** — Completed medical school at the West Virginia School of Osteopathic Medicine.
- **2008-2014** — Served in the United States Air Force, listed publicly at the rank of second lieutenant.
- **2012** — Co-founded GraftWorx, later renamed Alio, while preparing for surgical residency.
- **2021** — Alio closed a $20 million Series B financing; Kuraguntla received the Jon DeHaan Foundation Award for Innovation in Cardiology.
- **2022** — Alio received its first FDA clearance and announced an $18 million initial Series C close, taking disclosed cumulative funding above $50 million.
- **2023** — Alio received a subsequent FDA clearance covering additional measurements and began commercial availability in the United States.
- **2024** — Presented Alio's remote monitoring platform at LSI Europe and described commercial contracts, Medicare plan coverage, and planned strategic partnerships.
- **2025** — Served as a judge for Grove City College's Wolverine Venture Battle.

## Achievements

- Co-founded Alio in 2012 and led its evolution from an implantable sensor concept to an end-to-end wearable remote monitoring platform.
- Led Alio through multiple FDA 510(k) clearances, including K211365 and K223073.
- Led financing rounds including a $20 million Series B in 2021 and an $18 million initial Series C close in 2022.
- Co-authored peer-reviewed neuroscience research published in the Journal of Biological Chemistry in 2007.
- Received the Jon DeHaan Foundation Award for Innovation in Cardiology in 2021.
- Built partnerships publicly described with organizations including the NHS, Intermountain Healthcare, Lifeline Vascular Care and Carium.
- Served as a 2025 Wolverine Venture Battle judge at Grove City College.

## Latest updates

- **2025** — Served as a judge for the 2025 Wolverine Venture Battle at Grove City College.
- **2024-10** — Presented at LSI Europe, where he described new commercial contracts, Medicare plan coverage and an intended expansion into adjacent markets.
- **2024-06** — Appeared on Tech Talks with Holly Scott to discuss Alio's multi-metric wearable and product development.
- **2023-06** — Discussed Alio's founder journey, risk reduction, fundraising and strategic partnerships in a Medsider interview.

## Links

- Website: https://alio.ai
- LinkedIn: https://www.linkedin.com/in/davidkuraguntla

---

Profile page: https://yespress.io/david-kuraguntla
Published by YesPress — https://yespress.io
Last updated: 2026-08-18